#1 Clinical Trials Search in Europe

Inclisiran

Inclisiran is an innovative drug being studied in clinical trials for managing cholesterol levels, particularly in patients with high cardiovascular risk. This article explores the latest research on inclisiran’s effectiveness, safety, and potential to improve outcomes for people with conditions like atherosclerosis and hypercholesterolemia.

Table of Contents

What is Inclisiran?

Inclisiran is a new medication designed to lower cholesterol levels in the blood. It’s also known by other names such as KJX839, ALN-PCSSC, and Leqvio[1][2][3]. This drug is part of a class of medications called small interfering RNA (siRNA) drugs, which work in a unique way compared to traditional cholesterol-lowering medications like statins[4].

How Does Inclisiran Work?

Inclisiran works by targeting a protein in the body called PCSK9 (proprotein convertase subtilisin kexin type 9). This protein plays a role in controlling the levels of LDL cholesterol (often called “bad” cholesterol) in your blood. By reducing the amount of PCSK9, Inclisiran helps your body remove more LDL cholesterol from the bloodstream, leading to lower overall cholesterol levels[4].

What Conditions Does Inclisiran Treat?

Inclisiran is primarily used to treat conditions related to high cholesterol levels, including:

  • Primary Hypercholesterolemia: This is a condition where a person has naturally high levels of cholesterol in their blood[5].
  • Mixed Dyslipidemia: This refers to abnormal levels of multiple types of fats (lipids) in the blood, including cholesterol and triglycerides[5].
  • Familial Hypercholesterolemia: This is an inherited condition that leads to very high cholesterol levels from birth. It can be heterozygous (HeFH) or homozygous (HoFH), depending on whether a person inherits the condition from one or both parents[6].
  • Atherosclerotic Cardiovascular Disease (ASCVD): This is a condition where plaque builds up in the arteries, increasing the risk of heart attacks and strokes[1][3].

Inclisiran is often prescribed for patients who have tried other cholesterol-lowering medications, such as statins, but haven’t achieved their target cholesterol levels[1].

How is Inclisiran Administered?

Inclisiran is given as a subcutaneous injection, which means it’s injected just under the skin. The typical dose is 300 mg, usually given in the following schedule[1][2][3]:

  1. Initial dose
  2. Another dose after 3 months (90 days)
  3. Then every 6 months thereafter

This infrequent dosing schedule is one of the advantages of Inclisiran compared to some other cholesterol medications that need to be taken daily or weekly[1].

Effectiveness of Inclisiran

Clinical trials have shown that Inclisiran can be highly effective in lowering LDL cholesterol levels. Some key findings include:

  • Inclisiran can reduce LDL cholesterol by 50% or more in many patients[3].
  • It can help patients achieve target LDL levels of less than 70 mg/dL or even less than 55 mg/dL, which are recommended targets for high-risk patients[3].
  • The effects of Inclisiran appear to be long-lasting, with cholesterol reductions maintained over time with the twice-yearly dosing schedule[1].

Safety and Side Effects

Inclisiran has been studied in various patient populations, including those with kidney problems, and has generally been found to be well-tolerated[4]. However, like all medications, it can have side effects. Common side effects may include reactions at the injection site, such as pain or redness. More research is ongoing to fully understand the long-term safety profile of Inclisiran[5].

Ongoing Research

Several clinical trials are currently underway to further study Inclisiran. These studies are looking at:

  • The long-term safety and effectiveness of Inclisiran in different patient populations, including adolescents with familial hypercholesterolemia[6].
  • How Inclisiran compares to usual care in patients who have recently had a heart attack or other acute coronary syndrome[7].
  • The effects of Inclisiran on the buildup of plaque in the arteries, particularly in the carotid arteries that supply blood to the brain[2].
  • How Inclisiran performs in real-world settings, outside of controlled clinical trials[5].

These ongoing studies will help doctors and patients better understand how to use Inclisiran most effectively and safely in different situations.

Aspect Details
Drug Name Inclisiran
Mechanism PCSK9 inhibitor (small interfering RNA)
Administration Subcutaneous injection
Dosing Schedule Initial dose, 3 months later, then every 6 months
Primary Target LDL Cholesterol reduction
Patient Populations ASCVD, Familial Hypercholesterolemia, ACS, High cardiovascular risk
Key Outcomes LDL-C reduction, cardiovascular events, plaque stabilization
Safety Considerations Long-term effects, renal impairment, pediatric use
Comparative Studies Inclisiran + usual care vs. usual care alone
Additional Benefits Potential for improved adherence due to infrequent dosing

FAQ

  • What is inclisiran and how does it work? Inclisiran is a novel drug that lowers cholesterol by targeting PCSK9, a protein involved in cholesterol regulation. It works by interfering with PCSK9 production, which allows more LDL receptors to remove cholesterol from the blood.
  • Who might benefit from inclisiran treatment? Inclisiran is being studied for patients with high cholesterol levels despite taking statins, including those with conditions like atherosclerotic cardiovascular disease, familial hypercholesterolemia, and those who've had a recent acute coronary syndrome.
  • How is inclisiran administered? Inclisiran is given as a subcutaneous injection, typically administered by a healthcare professional. The dosing schedule in most trials involves an initial dose, followed by another at 3 months, and then every 6 months thereafter.
  • What are the main outcomes being studied in inclisiran trials? The primary outcomes in most inclisiran trials focus on its ability to lower LDL cholesterol levels, both in terms of percentage change and absolute reduction. Researchers are also studying its effects on other lipid markers, cardiovascular events, and long-term safety.
  • How does inclisiran compare to usual care for cholesterol management? Several trials are comparing inclisiran plus usual care to usual care alone. Early results suggest inclisiran may provide additional LDL cholesterol lowering beyond what can be achieved with standard therapies like statins.

Ongoing Clinical Trials on Inclisiran

  • Study of the efficacy and safety of inclisiran and a drug combination in patients with acute coronary syndrome

    Recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    France Germany Hungary Poland Spain

  • Study of pelacarsen and inclisiran in patients with atherosclerotic cardiovascular disease who have high levels of LDL cholesterol and lipoprotein(a)

    Recruiting

    1 1 1
    Investigated drugs:
    France Germany Italy The Netherlands Spain

  • Study on Inclisiran, Alirocumab, and Rosuvastatin for Children with Familial Hypercholesterolemia

    Recruiting

    1 1 1 1
    Investigated drugs:
    Poland

  • Study on the Safety and Effectiveness of Inclisiran in Children Aged 2 to Under 12 with Homozygous Familial Hypercholesterolemia

    Recruiting

    1 1 1
    Investigated drugs:
    Austria France Germany Greece The Netherlands Spain

  • Study on the Safety and Effectiveness of Inclisiran for Children Aged 6 to Under 12 with Familial Hypercholesterolemia

    Recruiting

    1 1 1
    Investigated drugs:
    Austria Belgium Czechia France Germany Greece +6

  • Study on the Effects of Alirocumab and Drug Combination on Hyperlipidemia in Patients

    Recruiting

    1 1 1 1
    Investigated drugs:
    Austria

  • Study on Long-Term Safety of Inclisiran for Patients with Familial Hypercholesterolemia Who Completed Previous Adolescent Studies

    Recruiting

    1 1 1 1
    Investigated drugs:
    Czechia France Germany Greece Hungary Italy +6

  • Inclisiran for Preventing Cardiovascular Events in High-Risk Primary Prevention Patients with Atherosclerotic Cardiovascular Disease

    Not recruiting

    1 1 1
    Investigated drugs:
    Austria Belgium Bulgaria Croatia Czechia Denmark +14

  • Study of inclisiran to prevent heart attacks and strokes in people with atherosclerotic cardiovascular disease

    Not recruiting

    1 1 1
    Investigated drugs:
    Austria Belgium Bulgaria Croatia Czechia Denmark +18

  • Study on Inclisiran and Rosuvastatin for Lowering Cholesterol in Patients with High Cholesterol Levels

    Not recruiting

    1 1 1
    Investigated drugs:
    Bulgaria Czechia Estonia France Germany Latvia +2

Glossary

  • LDL-C: Low-Density Lipoprotein Cholesterol, often called 'bad' cholesterol. High levels of LDL-C in the blood can lead to the buildup of plaque in arteries, increasing the risk of heart disease and stroke.
  • PCSK9: Proprotein Convertase Subtilisin Kexin Type 9, a protein that plays a role in regulating LDL cholesterol levels in the bloodstream. Inclisiran works by inhibiting the production of PCSK9.
  • Atherosclerosis: A condition where arteries become hardened and narrowed due to the buildup of plaque, which is made up of substances like cholesterol. This can lead to serious cardiovascular problems.
  • Acute Coronary Syndrome (ACS): A term used to describe a range of conditions associated with sudden, reduced blood flow to the heart, including heart attacks and unstable angina.
  • Familial Hypercholesterolemia (FH): An inherited condition characterized by very high levels of LDL cholesterol from birth, which significantly increases the risk of early heart disease.
  • Statin: A class of drugs commonly used to lower cholesterol levels by reducing the liver's production of cholesterol.
  • Subcutaneous Injection: A method of administering medication by injecting it into the layer of tissue between the skin and muscle.
  • Lipid Profile: A blood test that measures different types of fats (lipids) in your blood, including LDL cholesterol, HDL cholesterol, and triglycerides.
  • Cardiovascular Disease: A general term for conditions affecting the heart or blood vessels, often related to a process called atherosclerosis.
  • Pharmacokinetics: The study of how a drug is absorbed, distributed, metabolized, and eliminated by the body. This helps determine proper dosing and potential interactions.

References

  1. https://clinicaltrials.gov/study/NCT04929249
  2. https://clinicaltrials.gov/study/NCT06586684
  3. https://clinicaltrials.gov/study/NCT06249165
  4. https://clinicaltrials.gov/study/NCT03159416
  5. https://clinicaltrials.gov/study/NCT06386419
  6. https://clinicaltrials.gov/study/NCT05682378
  7. https://clinicaltrials.gov/study/NCT04873934